Genmab - Photo Credit: Andrei JackametsGenmab has stopped enrolling patients in an early-stage clinical trial for an experimental cancer drug it gained through the acquisition of ProfoundBio in April 2024 for €1.52 billion. This pause underscores a broader reshaping of its oncology strategy.
Tag Archive for: clinical trial
Last week, Genmab and AbbVie hit a setback with epcoritamab, after the bispecific T-cell-engaging antibody failed to deliver a survival benefit in a phase 3 study in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The EPCORE DLBCL-1 trial missed its primary endpoint of overall survival, the partners said on Friday. While epcoritamab did slow disease progression and performed better across several secondary measures, the survival miss overshadows the readout.
JJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data validate the programme’s safety and biological activity and clear the way for Phase II studies starting later this year.
uniqure Amsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for marketing authorisation next year. In addition, UniQure entered into a US$175m non-dilutive senior secured term loan facility with Hercules Capital and commenced a US$200m underwritten public offering of its ordinary shares to prepare a BLA in Q1 2026.